SynAct Pharma reported Q226 operating expenses of SEK24.6m, down 19% y-o-y, while the net loss narrowed to SEK22.0m and quarter-end cash stood at SEK14.2m. Post-period, the company secured a new financing facility of up to SEK100m from Fenja Capital, initially drawing SEK50m as convertible loans on more favourable terms than its previous SEK40m Hunter Capital facility, which has been terminated. Management reports a cash runway into Q327, providing greater flexibility to progress Phase III readiness for lead asset resomelagon and partnering activities.